THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) and UCB announced that the BRIDGE
study met the primary endpoint, demonstrating a statistically significant
increase in bone mineral density at the lumbar spine in men with osteoporosis
UCB has terminated its nearly 10-year-old collaboration with Immunomedics to develop and commercialize the latter’s lead candidate epratuzumab for all non-cancer indications worldwide. No reason for the termination was disclosed by Immunomedics...
THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) and UCB announced top-line results
from the Phase 3 placebo-controlled FRActure study in postmenopausal woMen with
ostEoporosis or FRAME. These data showed FRAME met the co-primary endpoints by
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to UCB SA (UCB-BT):